Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets.
inflammation
proteome
proximity extension assay (PEA)
psoriatic arthritis
synovial fluid (SF)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
12
2022
accepted:
10
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
1) To characterize the inflammatory proteome of synovial fluid (SF) from patients with Psoriatic Arthritis (PsA) using a high-quality throughput proteomic platform, and 2) to evaluate its potential to stratify patients according to clinical features. Inflammatory proteome profile of SF from thirteen PsA patients with active knee arthritis were analyzed using proximity extension assay (PEA) technology (Olink Target 96 Inflammation panel). Four patients with OA were included as control group. Seventy-nine inflammation-related proteins were detected in SF from PsA patients (SF-PsA). Unsupervised analyzes of the molecular proteome profile in SF-PsA identified two specific phenotypes characterized by higher or lower levels of inflammation-related proteins. Clinically, SF-PsA with higher levels of inflammatory proteins also showed increased systemic inflammation and altered glucose and lipid metabolisms. Besides, SF from PsA patients showed 39 out of 79 proteins significantly altered compared to SF-OA specifically related to cell migration and inflammatory response. Among these, molecules such as TNFα, IL-17A, IL-6, IL-10, IL-8, ENRAGE, CCL20, TNFSF-14, OSM, IFNγ, MCP-3, CXCL-11, MCP4, CASP-8, CXCL-6, CD-6, ADA, CXCL-10, TNFβ and IL-7 showed the most significantly change. This is the first study that characterizes the inflammatory landscape of synovial fluid of PsA patients by analyzing a panel of 92 inflammatory proteins using PEA technology. Novel SF proteins have been described as potential pathogenic molecules involved in the pathogenesis of PsA. Despite the flare, inflammatory proteome could distinguish two different phenotypes related to systemic inflammation and lipid and glucose alterations.
Identifiants
pubmed: 37033920
doi: 10.3389/fimmu.2023.1133435
pmc: PMC10073963
doi:
Substances chimiques
Proteome
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133435Informations de copyright
Copyright © 2023 Barbarroja, López-Montilla, Cuesta-López, Pérez-Sánchez, Ruiz-Ponce, López-Medina, Ladehesa-Pineda, López-Pedrera, Escudero-Contreras, Collantes-Estévez and Arias-de la Rosa.
Déclaration de conflit d'intérêts
Authors NB, CP-S and CL-M were co-founders of the company Cobiomic Bioscience S.L. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Rheumatol Int. 2013 Jan;33(1):265-6
pubmed: 22083617
Osteoarthr Cartil Open. 2022 Jul 07;4(3):100293
pubmed: 36474941
J Rheumatol. 1997 Mar;24(3):518-23
pubmed: 9058659
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
J Intern Med. 2022 May;291(5):676-693
pubmed: 35233860
Arthritis Rheum. 2011 Apr;63(4):914-22
pubmed: 21225692
Curr Rheumatol Rev. 2017;13(3):170-179
pubmed: 28460627
Clin Proteomics. 2014 Jul 01;11(1):27
pubmed: 25097465
Rheumatol Ther. 2019 Sep;6(3):305-315
pubmed: 31102105
Lancet. 2018 Jun 2;391(10136):2273-2284
pubmed: 29893226
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Rheumatology (Oxford). 2021 Feb 1;60(2):751-761
pubmed: 32793974